Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The IκB kinase (IKK) complex is a multi-subunit enzyme complex that serves as the master regulator of the nuclear factor-kappa B (NF-κB) signaling pathway, which is central to immune responses, inflammation, cell survival, and proliferation. The complex typically consists of two catalytic kinase subunits, IKKα (IKK1) and IKKβ (IKK2), and a regulatory subunit known as NEMO (NF-κB essential modulator or IKKγ). Upon activation by upstream stimuli such as cytokines, pathogens, or cellular stress, the IKK complex phosphorylates IκB inhibitor proteins, targeting them for polyubiquitination and subsequent degradation by the 26S proteasome. This degradation liberates NF-κB dimers, allowing them to translocate into the nucleus and drive the transcription of genes involved in inflammation, cell survival, and immune regulation. Dysregulation or chronic activation of the IKK/NF-κB pathway is implicated in a wide range of human pathologies, including chronic inflammatory diseases (such as rheumatoid arthritis and inflammatory bowel disease), autoimmune disorders, and various cancers where it promotes cell survival and chemoresistance. Consequently, the IKK complex has been a highly sought-after therapeutic target. While several small-molecule inhibitors (such as SAR-113945, IMD-0354, and BMS-345541) have been developed and evaluated in clinical trials, systemic inhibition of IKKβ has been severely limited by on-target toxicities, including profound immunosuppression and tissue damage. However, certain multi-target or repurposed drugs, such as the gold salt auranofin and the triterpenoid bardoxolone methyl, exert some of their anti-inflammatory and pro-apoptotic effects through the inhibition of the IKK complex.
Inhibition of the kinase activity of the IKK complex (specifically IKKβ and/or IKKα), preventing the phosphorylation and subsequent proteasomal degradation of IκB proteins, thereby keeping NF-κB sequestered in the cytoplasm and preventing its nuclear translocation and transcriptional activation of target genes.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on IκB kinase complex (IKK complex).